NCT06280105 A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
| NCT ID | NCT06280105 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Meng Chao Hepatobiliary Hospital of Fujian Medical University |
| Condition | Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-03-31 |
| Primary Completion | 2026-03-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib.
Eligibility Criteria
Inclusion Criteria: 1. Sign a written informed consent form before enrollment; 2. Age \>18 years old, both sex; 3. Histological or pathological confirmed intermediate or advanced hepatocellular carcinoma, or patients with cirrhosis who meet the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Study of Liver Diseases (AASLD); 4. Have progressed on the combination treatment of camrelizumab and apatinib for HCC 5. Child-Pugh Class A; 6. ECOG PS score: 0\~1; 7. At least 1 measurable lesion (RECIST1.1) 8. Expected survival period≥12 weeks 9. The function of vital organs meets the following requirements (excluding the use of any blood components and cell growth factors within 14 days): 1\. Blood routine: Neutrophils≥1.5×109/L Platelet count ≥75×109/L Hemoglobin ≥ 90g/L; 2. Liver and kidney function: Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 50 ml/min (Cockcroft-Gault formula); Total bilirubin (TBI
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.